Vera Therapeutics (VERA) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
On January 25, 2024, Vera Therapeutics announced promising 72-week results from its Phase 2b ORIGIN trial of atacicept for IgAN, a potential dual inhibitor therapy. The trial showed significant reductions in key indicators of IgAN and stable kidney function among participants. The company is progressing with a Phase 3 trial and anticipates submitting a biologics license application by the second half of 2025, with a potential commercial launch in 2026 if approved. The forward-looking statements highlight the company’s strategic plans and acknowledge the inherent risks and uncertainties in drug development and regulatory approval processes.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.